Explore how Terbium-161 outperforms Lutetium-177 in PSMA-targeted therapy for advanced prostate cancer. Now available weekly at FMRI Gurgaon, led by Dr. Ishita B. Sen, this cutting-edge treatment delivers superior precision and potency, offering new hope for better outcomes in nuclear oncology. https://nuclearmedicinetherapy.in/post/terbium-161-for-psma-targeted-radionuclide-therapy-of-prostate-cancer